Evidence map›Paper›PMID 25187476›Full record

ReviewThe oncologist2014

Genome-based risk prediction for early stage breast cancer.

Christina Adaniel, Komal Jhaveri, Adriana Heguy, Francisco J Esteva

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The oncologist, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Christina AdanielDivision of Hematology/Oncology, Laura and Isaac Perlmutter Cancer Center, and Genome Technology Center, New York University Langone Medical Center, New York, New York, USA.
Komal JhaveriDivision of Hematology/Oncology, Laura and Isaac Perlmutter Cancer Center, and Genome Technology Center, New York University Langone Medical Center, New York, New York, USA.
Adriana HeguyDivision of Hematology/Oncology, Laura and Isaac Perlmutter Cancer Center, and Genome Technology Center, New York University Langone Medical Center, New York, New York, USA.
Francisco J EstevaDivision of Hematology/Oncology, Laura and Isaac Perlmutter Cancer Center, and Genome Technology Center, New York University Langone Medical Center, New York, New York, USA francisco.esteva@nyumc.org.

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1M
NCI NIH HHS P30 CA016087
6 · The paper itself

Abstract

Tests to better characterize tumor genomic architecture are quickly becoming a standard of care in oncology. For breast cancer, the use of gene expression assays for early stage disease is already common practice. These tests have found a place in risk stratifying the heterogeneous group of stage I-II breast cancers for recurrence, for predicting chemotherapy response, and for predicting breast cancer-related mortality. In the last 5 years, more assays have become available to the practicing oncologist. Given the rapidity with which this field has evolved, it is prudent to review the tests, their indications, and the studies from which they have been validated. We present a comprehensive review of the available gene expression assays for early stage breast cancer. We review data for several individual tests and comparative studies looking at risk prediction and cost-effectiveness.

Indexed as

Gene Expression ProfilingBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleGenome, HumanHomeodomain ProteinsHumansReceptors, EstrogenReceptors, InterleukinReceptors, Interleukin-17RecurrenceRisk AssessmentERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesHomeodomain ProteinsHOXB13 protein, humanIL17RB protein, humanReceptors, EstrogenReceptors, InterleukinReceptors, Interleukin-17Breast cancerGene expressionGenomic profiling

Identifiers

PMID25187476
PMCPMC4200995

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.